3-413: α-Difluoromethyl-3,4-dihydroxyphenylalanine ( DFMD , DFM-DOPA ) is a DOPA decarboxylase inhibitor . Stimulants: Phenylethanolamine DOPA decarboxylase inhibitor An aromatic L -amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor , extracerebral decarboxylase inhibitor , DDCI and AAADI ) is a medication of type enzyme inhibitor which inhibits
6-451: A result of interaction with D 2 receptors in the vomiting center (or cheomoreceptor trigger zone) located outside the blood–brain barrier . Examples of extracerebral decarboxylase inhibitors include carbidopa and benserazide . Peripherally selective DDCIs incapable of crossing the protective blood–brain barrier (BBB) are used in augmentation of L -DOPA (levodopa) in the treatment of Parkinson's disease (PD) to block
9-403: The synthesis of dopamine by the enzyme aromatic L -amino acid decarboxylase (AADC, AAAD, or DOPA decarboxylase). It is used to inhibit the decarboxylation of L -DOPA to dopamine outside the brain, i.e. in the blood . This is primarily co-administered with L -DOPA to combat Parkinson's disease . Administration can prevent common side-effects, such as nausea and vomiting, as
#638361